GB201513743D0 - Muscarinic agonists - Google Patents

Muscarinic agonists

Info

Publication number
GB201513743D0
GB201513743D0 GBGB1513743.3A GB201513743A GB201513743D0 GB 201513743 D0 GB201513743 D0 GB 201513743D0 GB 201513743 A GB201513743 A GB 201513743A GB 201513743 D0 GB201513743 D0 GB 201513743D0
Authority
GB
United Kingdom
Prior art keywords
muscarinic agonists
muscarinic
agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1513743.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Priority to GBGB1513743.3A priority Critical patent/GB201513743D0/en
Publication of GB201513743D0 publication Critical patent/GB201513743D0/en
Priority to EP16750222.8A priority patent/EP3331529B1/en
Priority to DK16750222.8T priority patent/DK3331529T3/da
Priority to US15/749,957 priority patent/US10738029B2/en
Priority to CN201680045224.1A priority patent/CN108025004B/zh
Priority to AU2016304387A priority patent/AU2016304387B2/en
Priority to ES16750222T priority patent/ES2894637T3/es
Priority to HK18109572.7A priority patent/HK1250138B/en
Priority to JP2018504992A priority patent/JP6843114B2/ja
Priority to PCT/GB2016/052385 priority patent/WO2017021729A1/en
Priority to CA2994203A priority patent/CA2994203C/en
Priority to US16/942,167 priority patent/US11254656B2/en
Priority to US17/672,302 priority patent/US12024499B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB1513743.3A 2015-08-03 2015-08-03 Muscarinic agonists Ceased GB201513743D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB1513743.3A GB201513743D0 (en) 2015-08-03 2015-08-03 Muscarinic agonists
CA2994203A CA2994203C (en) 2015-08-03 2016-08-03 Azaspiro compounds as muscarinic agonists
ES16750222T ES2894637T3 (es) 2015-08-03 2016-08-03 Agonistas muscarínicos
DK16750222.8T DK3331529T3 (da) 2015-08-03 2016-08-03 Muskarinagonister
US15/749,957 US10738029B2 (en) 2015-08-03 2016-08-03 Muscarinic agonists
CN201680045224.1A CN108025004B (zh) 2015-08-03 2016-08-03 毒蕈碱激动剂
AU2016304387A AU2016304387B2 (en) 2015-08-03 2016-08-03 Muscarinic agonists
EP16750222.8A EP3331529B1 (en) 2015-08-03 2016-08-03 Muscarinic agonists
HK18109572.7A HK1250138B (en) 2015-08-03 2016-08-03 Muscarinic agonists
JP2018504992A JP6843114B2 (ja) 2015-08-03 2016-08-03 ムスカリン作動薬
PCT/GB2016/052385 WO2017021729A1 (en) 2015-08-03 2016-08-03 Muscarinic agonists
US16/942,167 US11254656B2 (en) 2015-08-03 2020-07-29 Muscarinic agonists
US17/672,302 US12024499B2 (en) 2015-08-03 2022-02-15 Muscarinic agonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1513743.3A GB201513743D0 (en) 2015-08-03 2015-08-03 Muscarinic agonists

Publications (1)

Publication Number Publication Date
GB201513743D0 true GB201513743D0 (en) 2015-09-16

Family

ID=54063149

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1513743.3A Ceased GB201513743D0 (en) 2015-08-03 2015-08-03 Muscarinic agonists

Country Status (10)

Country Link
US (3) US10738029B2 (enExample)
EP (1) EP3331529B1 (enExample)
JP (1) JP6843114B2 (enExample)
CN (1) CN108025004B (enExample)
AU (1) AU2016304387B2 (enExample)
CA (1) CA2994203C (enExample)
DK (1) DK3331529T3 (enExample)
ES (1) ES2894637T3 (enExample)
GB (1) GB201513743D0 (enExample)
WO (1) WO2017021729A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033114T2 (en) 2011-11-18 2017-11-28 Heptares Therapeutics Ltd Muscarin M1 receptor agonists
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
EP3697781B1 (en) * 2017-10-17 2023-06-07 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
TWI801540B (zh) 2018-03-23 2023-05-11 美商輝瑞大藥廠 哌嗪氮雜螺衍生物
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
CR20220153A (es) * 2019-10-09 2022-05-03 Novartis Ag Derivados de 2–azaespiro [3.4] octano como agonistas de m4
UY38906A (es) 2019-10-09 2021-05-31 Novartis Ag Compuestos 2- derivados de azaspiro[3,4]octano como agonistas de m4 y composiciones de los mismos

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369184A (en) 1980-01-24 1983-01-18 Janssen Pharmaceutica N.V. 1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives
JPS56110674A (en) 1980-01-24 1981-09-01 Janssen Pharmaceutica Nv Novel 11*cyclohexyl**44aryll44piperidine carboxylic acid derivative
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
GB9300194D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
JP2002515008A (ja) 1994-10-27 2002-05-21 メルク エンド カンパニー インコーポレーテッド ムスカリン・アンタゴニスト
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
WO1997016187A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine antagonists
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
AU3632297A (en) 1996-08-26 1998-03-19 Pfizer Inc. Spirocyclic dopamine receptor subtype ligands
WO1998057641A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
GB9715892D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
AU2095099A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparationand their use as muscarinic receptor (ant-)agonists
AU2206699A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
AU2307899A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
AU2307999A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
CZ286152B6 (cs) 1998-03-13 2000-01-12 Miroslav Ing. Csc. Vlček Transparentní a semitransparentní difrakční prvky
CN1118452C (zh) 1998-04-28 2003-08-20 大日本制药株式会社 1－[(1－取代－4－哌啶基)甲基]－4－哌啶衍生物、其生产方法、含有该化合物的药物组合物和这些化合物的中间体
PL203117B1 (pl) 1999-05-04 2009-08-31 Schering Corp Piperydynopiperydynowa pochodna użyteczna jako antagonista CCR5, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
EP1175224B1 (en) 1999-05-04 2005-02-23 Schering Corporation Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
WO2001019816A1 (en) 1999-09-13 2001-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
DE60013464T2 (de) 1999-10-13 2005-09-15 Banyu Pharmaceutical Co., Ltd. Substituierte imidazolin-derivate
AU2001297648A1 (en) 2000-11-28 2002-08-28 Eli Lilly And Company Substituted carboxamides as inhibitors of factor xa
WO2002085890A1 (en) 2001-04-20 2002-10-31 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
US7067507B2 (en) 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
GB0128378D0 (en) 2001-11-27 2002-01-16 Smithkline Beecham Plc Novel Compounds
RU2292346C2 (ru) 2001-12-28 2007-01-27 Акадиа Фармасьютикалз, Инк. Гетероциклические мускариновые агонисты и композиции, их применение и способы лечения
US7550459B2 (en) 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
US20040171614A1 (en) 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors
US7256186B2 (en) 2002-02-06 2007-08-14 Schering Corporation Gamma secretase inhibitors
DE60330847D1 (de) 2002-03-28 2010-02-25 Mitsubishi Tanabe Pharma Corp Benzofuranderivat
EP1552842A1 (en) 2002-06-07 2005-07-13 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
AU2002368152A1 (en) 2002-07-31 2004-02-25 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo (3.1.0)hexane derivatives useful as muscarinic receptor antagonists
RU2323218C2 (ru) 2002-09-30 2008-04-27 НьюроСёрч А/С Новые производные 1,4-диазабициклоалкана и фармацевтическая композиция на их основе
NZ539952A (en) 2002-11-22 2008-05-30 Japan Tobacco Inc Fused bicyclic nitrogen-containing heterocyclic compounds for treating diabetes, obesity and syndrome X
PL376925A1 (pl) 2002-11-27 2006-01-09 Incyte Corporation Pochodne 3-aminopirolidyny jako modulatory receptorów chemokiny
JPWO2004069828A1 (ja) 2003-02-04 2006-05-25 三菱ウェルファーマ株式会社 ピペリジン化合物およびその医薬用途
MXPA06000441A (es) 2003-07-17 2006-04-05 Astellas Pharma Inc Derivado de 2-acilaminotiazole o sal del mismo.
JPWO2005037269A1 (ja) 2003-10-21 2006-12-28 住友製薬株式会社 新規ピペリジン誘導体
CA2554465A1 (en) 2004-02-05 2005-08-25 Schering Corporation Piperidine derivatives useful as ccr3 antagonists
JP2007522160A (ja) 2004-02-10 2007-08-09 エフ．ホフマン−ラ　ロシュ　アーゲー ケモカインｃｃｒ５受容体モジュレーター
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
EP1817032A2 (en) 2004-11-29 2007-08-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
JP4774995B2 (ja) 2005-01-12 2011-09-21 アステラス製薬株式会社 アシルアミノチアゾール誘導体を有効成分とする医薬組成物
EP1863490A2 (en) 2005-03-28 2007-12-12 Vertex Pharmaceuticals Incorporated Muscarinic modulators
WO2006137485A1 (ja) 2005-06-24 2006-12-28 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
US7858635B2 (en) 2005-12-22 2010-12-28 Vertex Pharmaceuticals Incorporated Spiro compounds as modulators of muscarinic receptors
US7772231B2 (en) 2005-12-29 2010-08-10 Abbott Laboratories Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors
AU2007221214A1 (en) 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CA2642649A1 (en) * 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2008021375A2 (en) 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EA200900821A1 (ru) 2006-12-22 2010-02-26 Новартис Аг Производные 1-аминометил-l-фенилциклогексана как ингибиторы дпп-iv (дипептидилпептидазы-iv)
WO2008117229A1 (en) 2007-03-23 2008-10-02 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
US20090221567A1 (en) 2008-02-28 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof 177
EP2274301B1 (en) 2008-03-27 2012-09-26 Janssen Pharmaceutica, N.V. Aza-bicyclohexyl substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
AU2009309988A1 (en) 2008-10-29 2010-05-06 Grunenthal Gmbh Substituted spiroamines
AU2009327127C1 (en) 2008-12-19 2017-03-09 Centrexion Therapeutics Corporation Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD
MX2011010964A (es) 2009-04-17 2011-11-02 Janssen Pharmaceutica Nv Antagonistas del receptor 2 de citocina quimioatrayente de 4- azetidinil-1-fenil-ciclohexano.
FR2945531A1 (fr) 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
WO2011112825A2 (en) 2010-03-10 2011-09-15 Vanderbilt University Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective m1 agonists and methods of making and using same
AU2011242711C1 (en) 2010-04-22 2016-04-21 Janssen Pharmaceutica Nv Indazole compounds useful as ketohexokinase inhibitors
EP2563127A4 (en) 2010-04-27 2013-11-06 Merck Sharp & Dohme PROLYLCARBOXYPEPTIDASE INHIBITORS
EP2568812B1 (en) 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
WO2011150183A1 (en) 2010-05-28 2011-12-01 Ge Healthcare Limited Radiolabeled compounds and methods thereof
CA2811525A1 (en) 2010-09-17 2012-03-22 Array Biopharma Inc. Piperidinyl-substituted lactams as gpr119 modulators
EP2685828A4 (en) 2011-03-17 2014-08-13 Merck Sharp & Dohme SUBSTITUTED 3-AZABICYCLO [3,1,0-] HEXAN DERIVATIVES AS CCR2 ANTAGONISTS
JP2013010719A (ja) 2011-06-30 2013-01-17 Dainippon Sumitomo Pharma Co Ltd ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
HUE033114T2 (en) 2011-11-18 2017-11-28 Heptares Therapeutics Ltd Muscarin M1 receptor agonists
CA2883210C (en) 2012-09-18 2021-06-15 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists
US9593106B2 (en) 2013-02-07 2017-03-14 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
RS65894B1 (sr) 2014-02-06 2024-09-30 Nxera Pharma Uk Ltd Biciklična aza jedinjenja kao agonisti muskarinskog receptora
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
ES2734734T3 (es) 2015-02-13 2019-12-11 Suven Life Sciences Ltd Compuestos de amida como agonistas del receptor 5-HT4
GB201504675D0 (en) * 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513740D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
US10259787B2 (en) 2016-10-14 2019-04-16 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
GB201709652D0 (en) 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
TW201922758A (zh) 2017-10-24 2019-06-16 美商歐樂根公司 烯胺及烯胺的非鏡像選擇性還原
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202103211D0 (en) 2021-03-08 2021-04-21 Heptares Therapeutics Ltd Pharmaceutical compounds for use in therapy

Also Published As

Publication number Publication date
US12024499B2 (en) 2024-07-02
AU2016304387B2 (en) 2020-10-22
US20200354339A1 (en) 2020-11-12
US11254656B2 (en) 2022-02-22
CA2994203C (en) 2023-11-28
EP3331529A1 (en) 2018-06-13
JP2018522033A (ja) 2018-08-09
WO2017021729A1 (en) 2017-02-09
CN108025004A (zh) 2018-05-11
US20180222885A1 (en) 2018-08-09
AU2016304387A1 (en) 2018-02-22
CA2994203A1 (en) 2017-02-09
CN108025004B (zh) 2021-07-09
EP3331529B1 (en) 2021-09-29
HK1250138A1 (en) 2018-11-30
ES2894637T3 (es) 2022-02-15
US10738029B2 (en) 2020-08-11
DK3331529T3 (da) 2021-10-18
US20230002354A1 (en) 2023-01-05
JP6843114B2 (ja) 2021-03-17

Similar Documents

Publication Publication Date Title
ZA201800715B (en) Muscarinic agonists
GB201513740D0 (en) Muscarinic agonist
GB201513743D0 (en) Muscarinic agonists
AP2016009445A0 (en) Muscarinic receptor agonists
GB201505527D0 (en) Composition
GB201506827D0 (en) Composition
IL254550A0 (en) Toilet paper roll holder
GB201506829D0 (en) Composition
GB201506825D0 (en) Composition
EP3265466A4 (en) Peripheral-anticholinergic muscarinic agonist combination
GB201504665D0 (en) Composition
GB201522309D0 (en) Use
GB201522311D0 (en) Use
GB201504307D0 (en) Composition
GB201506828D0 (en) Composition
GB201505520D0 (en) Composition
PT3370756T (pt) Combinação de canrenoato e exenatido
GB201521085D0 (en) Use
GB201506826D0 (en) Composition
GB201518466D0 (en) Use
GB201510077D0 (en) Use
GB201519573D0 (en) Combination
GB201509839D0 (en) One piece
GB201500297D0 (en) Agonists
HUE052800T2 (hu) Kontrasztanyagok

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)